Shares of 20/20 Biolabs (AIDX) rose 7.7% to $0.56 as investors digested what the company called its strongest-ever quarter for its AI-powered cancer blood test. The results show genuine commercial traction — but the math between top-line growth and bottom-line losses demands scrutiny.
• Cancer Testing Revenue Hit a Record, but the Base Is Tiny
Total revenue increased 36.5% to $0.7 million in Q2 2026, with the company's cancer blood test accounting for 95.3% of total revenue, up from 88.4% a year earlier.
Revenue from that flagship test alone jumped 47.1% year over year to $0.7 million. That sounds impressive in percentage terms, but this is still a sub-$1 million quarter for a public company. The stock's entire market capitalization sits at roughly $6.15 million — smaller than many seed-stage startups.
• Margins Improved Sharply as the Lab Ran More Tests
Gross profit surged 86.6% to $0.3 million, with gross margin expanding to 41.7% from 30.5%, reflecting better absorption of fixed laboratory costs across a higher volume of tests. The jump from Q1's dismal 17.8% gross margin shows how volume-sensitive this business model is: more tests through one lab in Gaithersburg, Maryland means each one costs less to run. If firefighter screening contracts deliver as promised, this trend could continue.
• Government Contracts Are the Near-Term Growth Engine
State-funded firefighter cancer screening programs gained momentum — Vermont selected the test to screen up to 4,500 firefighters, Maryland awarded $520,000 for screenings, and management expects these programs alone to generate over $1.0 million through year-end. That pipeline is meaningful relative to the company's scale, but it hinges on government funding cycles and program renewals.
• Losses Are Still Growing Faster Than Revenue
The net loss for the first half of 2026 was $3.7 million, compared to $1.6 million a year earlier , though roughly $1.7 million of that was non-cash charges.
Analysts have flagged that AIDX has "less than 1 year of cash runway" and negative shareholders' equity.
A $5 million private placement in February — part of a facility allowing up to $40 million — provided a lifeline, but these capital raises dilute existing shareholders and have contributed to the stock's steep decline from a 52-week high near $19.
The bottom line: 20/20 Biolabs is proving it can sell its cancer test. What it hasn't proven is that it can do so fast enough to outrun its cash burn — the central question for any investor at $0.56.